Journals / MN Kardiyoloji / 2003 / Cilt: 10 - Sayı: 3

The effects of atorvastatin on high sensitivity-CRP in the hyperlipidemic patients with and without coronary artery disease

Koroner arter hastalığı olan ve olmayan hiperlipidemili hastalarda atorvastatinin high sensitive CRP düzeylerine etkisi

Pages
174–177
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Median hs-CRP levels decreased from 0.37mg/dl to 0.16mg/dl after therapy in Patients with CAD. in patients vvithout CAD median hs-CRP levels decreased from 0.36mg/dl to 0.16 mg/dl. in the both group the reduction of CRP levels was significant (respectively p<0.0001 and 0.0001) and similar to each other- There was no correlation betvveen reductions in the hs-CRP and LDL cholesterol (r=-0.2, p=0.1). conclusion; As a result, atorvastatin significantly decreased hs-CRP levels in patients with and without CAD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim it is demonstrated that baseline levels of C-reactive protein (CRP) which is a marker of inflammation are associated with increased risk of coronary events.
📊
Key Findings & Data:Small increases CRP levels even in normal range can increase cardiovascular risk.
💡
Conclusion & Impact:Median hs-CRP levels decreased from 0.37mg/dl to 0.16mg/dl after therapy in Patients with CAD. in patients vvithout CAD median hs-CRP levels decreased from 0.36mg/dl to 0.16 mg/dl. in the both group the reduction of CRP levels was significant (respectively p<0.0001 and 0.0001) and similar to each other- There was no correlation betvveen reductions in the hs-CRP and LDL cholesterol (r=-0.2, p=0.1). conclusion; As a result, atorvastatin significantly decreased hs-CRP levels in patients with and without CAD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Antikolesteremik ajanlar · C-reaktif protein · Koroner arteriyoskleroz

Abstract

Aim it is demonstrated that baseline levels of C-reactive protein (CRP) which is a marker of inflammation are associated with increased risk of coronary events. Small increases CRP levels even in normal range can increase cardiovascular risk. Beyond lipid lovvering effects of statins they may have anti-inflamatuar effects. in this study he effects of atorvastatin on high-sensitivity CRP (hs-CRP) in the hyperlipidemic patients with and vvithout coronary artery disease (CAD) was investigated. material and Method: Thirty two patients with CAD and 32 patients without CAD (total 64) were started on 10 mg atorvastatin for 8 vveeks. We measured total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol and hsCRP levels at baseline and after 8 vveeks of therapy. Result: in the both group total cholesterol, triglyceride and LDL cholesterol decreased significantly. There was no significant effect on HDL cholesterol. Median hs-CRP levels decreased from 0.37mg/dl to 0.16mg/dl after therapy in Patients with CAD. in patients vvithout CAD median hs-CRP levels decreased from 0.36mg/dl to 0.16 mg/dl. in the both group the reduction of CRP levels was significant (respectively p<0.0001 and 0.0001) and similar to each other- There was no correlation betvveen reductions in the hs-CRP and LDL cholesterol (r=-0.2, p=0.1). conclusion; As a result, atorvastatin significantly decreased hs-CRP levels in patients with and without CAD.

Özet

Amaç: Enflamasyonun bir göstergesi olan C-reaktif proteinin (CRP) artmış koroner olay riski ile ilişkili olduğu gösterilmiştir. CRP'nin normal değerleri içindeki hafif artış bile kardiyovasküler olay riskini arttırmaktadır. Statinlerin LDL-kolesterolü düşürücü etkisinin yanı sıra antiinflamatuar etkisi de söz konusudur. Bu çalışmada koroner arter (KAH) hastalığı olan ve olmayan hiperlipidemili olgularda atorvastatinin yüksek hassasiyetli CRP (hs-CRP) üzerine etkisi araştırıldı. Gereç ve Yöntem: Koroner arter hastalığı olan 32 ve olmayan 32 hiperlipidemili (toplam 64) hastaya günde 10 mg atorvastatin 8 hafta süreyle verildi. Tedavi öncesi ve 8 haftalık tedavi sonrası total kolesterol, trigliserid, HDL kolesterol ve LDL kolesterol ile hs-CRP düzeylerine bakıldı. Bulgular: Her iki grupta da total kolesterol, trigliserid ve LDL kolesterol düzeyleri anlamlı şekilde düştü. HDL kolesterol düzeyindeki değişiklik anlamlı değildi. KAH olan grupta ortanca CRP değeri 0.37 mg/dl'den tedavi sonrası 0.16 mg/dl'ye geriledi. KAH olmayan grupta ise 0.36 mg/dl'den 0.18 mg/dl'ye gerileme gösterdi. Her iki grupta da hs-CRP düzeyindeki azalma istatistiksel olarak anlamlıydı (sırasıyla p<0.0001 ve 0.0001) ve bu azalma her iki , grupta da benzerdi. LDL kolesterol ile hs-CRP düzeyindeki değişiklikler arasında korelasyon saptanmadı (r=-0.2, p=0.1). i Sonuç: Sonuç olarak KAH olan ve olmayan hiperlipidemili hastalarda atorvastatin lipid düşürücü etkisinden bağımsız olarak hs-CRP düzeylerini anlamlı olarak azalttığı saptandı.

🔖

Cite This Article

YEŞİLBURSA, D., SERDAR, O. A., COŞKUN, Ş., SARAÇ, M., MEHMETOĞLU, E., DOĞAN, F., COŞKUN, Y., KAZAZOĞLU, A. R., CORDAN, J. (2003). The effects of atorvastatin on high sensitivity-CRP in the hyperlipidemic patients with and without coronary artery disease. MN Kardiyoloji, Cilt: 10 - Sayı: 3, 174–177. https://ajindex.com/articles/297813

References (12)

  1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH- Inflammation, aspirin and the risk of cardiovas­cular disease in Healthy men. N Eng J Med 1997; 336:973-9.
  2. Ridker PM, Hennekens CH, Buring JE, et al. C-Reactive Pro tein and other markers of inflamation in the prediction of cardio vascular disease in women. N Eng J Med 2000; 342:836-43. Ridker PM. High-sensitity C-reactive protein potential adjunct for global risk assessment in the primary pervention of cardiovascular disease. Circulation. 2001; 103:1813-8.
  3. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-Reactive Protein and serum amyloid a protein in severe unstable angina. N Engl Med. 1994; 331:417-24.
  4. Haverkate F, Thompson SG, Pyke SDM, et al. Production of C-Reactive Protein and risk of coronary events in the stable and unstable angina. Lancet. 1997; 349:462-6.
  5. Ridker PM, Rifai N, Pfeffer MA, et al. For the cholesterol and recurrent events (CARE) investigators inflamation, pravastatin and the risk of coronary events after myocardial infarction in patients with avarage cholesterol levels. Circulation. 1998; 98:839-44.
  6. Maron DJ, Fazio S, MacRare FL. Current perspectives on statins. Circulation. 2000; 101:207-13.
  7. Rosenson RS, Christine CT. Antiatherothrombic properties of statins. JAMA. 1998; 279:1643-50.
  8. Friedewald WT, Levy Rl, Frederickson DS. Estimation of concentration of low density lipoprotein cholesterol in plasma, without the use preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
  9. Jukema JW, Bruschke AVG, vanBoven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS) Circulation 1995; 91:2528-40.
  10. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disesase: prospective study and updated meta-analysis. BMJ 2000; 321:199-204.
  11. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959-65.
  12. De Maat MP, Kluft C, Hoogerbrugge N. No effect of pravastatin on C-reactive protein and fibrinogen level. Fibrinolysis Proteolysis 1999; 13 (Suppl 1):29. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Deveraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circ